Study on the efficacy and safety of tiotropium bromide and budesonide/formoterol treatment in chronic obstructive pulmonary disease
10.3760/cma.j.issn.1673-4904.2010.22.005
- VernacularTitle:噻托溴铵和布地奈德/福莫特罗治疗慢性阻塞性肺疾病的疗效与安全性研究
- Author:
Jianqing ZHANG
;
Ling LIU
;
Lizhou FANG
;
Zhihuan ZHAO
;
Luming DAI
- Publication Type:Journal Article
- Keywords:
Pulmonary,chronic obstructive;
Budesonide;
Tiotropium bromide;
Formoterol;
Respiratory function tests
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(22):12-15
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of inhaled tiotropium bromide combined with budesonide/formoterol on reducing the frequency of acute episodes of symptom exacerbation and improving lung function,health status in chronic obstructive pulmonary disease (COPD). Methods Eighty-six patients with COPD were divided into 3 groups, combination group[29 cases, inhaled budesonide/formoterol (160 μg/4.5 μg, twice one day ) and tiotropium bromide ( 18 μg, once one day)], budesonide/formoterol group( 29 cases, 160 μg/4.5 μg, twice one day) and tiotropium bromide group(28 cases, 18 μg, once one day). The treatment continued for 3 months. Results Lung function, symptoms and health status improved obviously in three groups. The forced expiratory volume in one second (FEV1) of combination group after treatment was (1.24±0.18) L , which was improved by 11.7% compared with before treatment. It was significantly higher than that in budesenide/formoterol group and fiotropium bromide group (P < 0.01 ). The rescue medication consumptions and the times of acute episode of combination group were significantly decreased compared with those in the other groups,and there was significant difference (P <0.01). The SGRQ score of combination group was (35.6±13.9) points which was significantly lower than that of budesonide/formoterol group and tiotropium bromide group,and there was significant difference (P < 0.01 ).There was no statistical difference in the adverse events occurred in three groups (P > 0.05 ). Conclusions Combination treatment produces better control of symptoms and lung function and has no greater risk of sideeffects, compared with the treatment of budesonide/formoterol alone and tiotropium bromide alone. The combination treatment should be considered for patients with COPD.
